Oryzon Genomics SA
MAD:ORY
Oryzon Genomics SA
MAD:ORY
Price:
2.81
EUR
0.9%
Market Closed
Market Cap:
€224.5m
Balance Sheet
Balance Sheet Decomposition
Oryzon Genomics SA
Oryzon Genomics SA
Balance Sheet Decomposition is not available for
Oryzon Genomics SA
Oryzon Genomics SA
Balance Sheet
Oryzon Genomics SA
Oryzon Genomics SA
Currency: EUR
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
2
|
2
|
4
|
19
|
22
|
35
|
34
|
35
|
40
|
29
|
21
|
12
|
6
|
28
|
|
| Cash |
0
|
0
|
0
|
19
|
22
|
35
|
34
|
35
|
40
|
29
|
21
|
12
|
6
|
25
|
|
| Cash Equivalents |
2
|
2
|
4
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
|
| Short-Term Investments |
1
|
0
|
6
|
2
|
5
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
4
|
4
|
2
|
3
|
2
|
|
| Accounts Receivables |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
2
|
2
|
4
|
4
|
2
|
3
|
2
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
4
|
3
|
10
|
23
|
28
|
36
|
36
|
38
|
42
|
33
|
25
|
14
|
9
|
31
|
|
| PP&E Net |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| PP&E Gross |
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
1
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
1
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
|
| Intangible Assets |
15
|
16
|
13
|
15
|
19
|
22
|
29
|
40
|
49
|
60
|
76
|
90
|
98
|
109
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
1
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
4
|
|
| Total Assets |
23
N/A
|
23
+2%
|
26
+13%
|
41
+56%
|
50
+22%
|
61
+23%
|
67
+11%
|
80
+19%
|
94
+18%
|
95
+1%
|
104
+9%
|
107
+3%
|
110
+3%
|
145
+32%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
1
|
0
|
1
|
2
|
2
|
1
|
2
|
3
|
2
|
3
|
5
|
3
|
2
|
3
|
|
| Accrued Liabilities |
0
|
0
|
0
|
1
|
0
|
0
|
0
|
0
|
1
|
1
|
0
|
1
|
0
|
1
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
3
|
4
|
3
|
0
|
|
| Current Portion of Long-Term Debt |
1
|
2
|
1
|
1
|
4
|
6
|
7
|
6
|
4
|
3
|
7
|
6
|
5
|
5
|
|
| Other Current Liabilities |
1
|
1
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
1
|
3
|
2
|
1
|
8
|
|
| Total Current Liabilities |
2
|
3
|
4
|
5
|
8
|
9
|
10
|
11
|
8
|
9
|
19
|
16
|
12
|
16
|
|
| Long-Term Debt |
8
|
9
|
6
|
3
|
18
|
13
|
7
|
4
|
5
|
10
|
7
|
3
|
3
|
3
|
|
| Deferred Income Tax |
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
2
|
4
|
|
| Other Liabilities |
0
|
0
|
0
|
3
|
0
|
3
|
3
|
3
|
3
|
3
|
3
|
3
|
4
|
4
|
|
| Total Liabilities |
12
N/A
|
14
+14%
|
12
-13%
|
13
+8%
|
27
+106%
|
27
-2%
|
22
-16%
|
19
-15%
|
18
-4%
|
24
+33%
|
31
+29%
|
25
-19%
|
22
-14%
|
27
+23%
|
|
| Equity | |||||||||||||||
| Common Stock |
0
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
3
|
3
|
3
|
3
|
3
|
4
|
|
| Retained Earnings |
9
|
11
|
4
|
7
|
12
|
19
|
21
|
26
|
5
|
10
|
14
|
18
|
21
|
25
|
|
| Additional Paid In Capital |
14
|
14
|
14
|
30
|
30
|
48
|
61
|
80
|
74
|
74
|
80
|
92
|
101
|
132
|
|
| Treasury Stock |
0
|
0
|
2
|
2
|
2
|
2
|
2
|
1
|
1
|
1
|
1
|
1
|
2
|
6
|
|
| Other Equity |
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
5
|
7
|
12
|
|
| Total Equity |
10
N/A
|
9
-13%
|
14
+54%
|
28
+99%
|
23
-18%
|
34
+51%
|
45
+31%
|
61
+35%
|
76
+24%
|
71
-6%
|
73
+2%
|
82
+13%
|
88
+8%
|
118
+34%
|
|
| Total Liabilities & Equity |
23
N/A
|
23
+2%
|
26
+13%
|
41
+56%
|
50
+22%
|
61
+23%
|
67
+11%
|
80
+19%
|
94
+18%
|
95
+1%
|
104
+9%
|
107
+3%
|
110
+3%
|
145
+32%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
23
|
23
|
23
|
27
|
28
|
33
|
38
|
45
|
53
|
53
|
55
|
61
|
65
|
78
|
|
Switch to:
Switch to:
See Also
Discover More
